Synthon Pharmaceuticals.

PositionTriangle - Brief Article

CHAPEL HILL -- Synthon Pharmaceuticals has received FDA approval for an antidepressant that it hopes will challenge GlaxoSmithKline's Paxil. Synthon, the U.S. subsidiary of Netherlands-based Synthon Holdings, says its yet-to-be named drug could cost 40% less than Paxil. Synthon plans to begin marketing it by the end of...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT